Cure My Disease

Don't miss your cure!

 Log in / Sign up

Poop pills vs. superbugs: new hope against Antibiotic-Resistant infections

NCT ID NCT05742074

Disease control Sponsor: Hvidovre University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether transplanting healthy donor stool (fecal microbiota transplantation, or FMT) into the gut could wipe out multidrug-resistant organisms (MROs) in 83 adult carriers. The goal was to prevent future hard-to-treat infections. Participants swallowed capsules containing either donor stool or a placebo, and researchers checked rectal samples for MRO clearance after 8 and 16 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

83 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 110 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: minimum 18 years * Positive rectal PCR and/or culture for MRO * Ability to speak and understand Danish or English * Capable of swallowing the capsules Exclusion Criteria: * Current invasive infection with an MRO e.g. in abdomen, bloodstream or symptomatic urinary tract infection. * Severe immune deficiency (defined as current chemo treatment or neurofilocytes \< 1000/mm3 * Pancreatitis, defined by pancreatic amylases above the upper reference limit * Planned or recent abdominal surgery (within 14 days) * Parenteral nutrition * Current antibiotic treatment of the same MRO as intestinal carriage * Terminal disease with expected survival under three months * Sepsis defined according to Surviving Sepsis Campaign guidelines * Pregnant or lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Faecal microbiota transplantation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Faecal microbiota transplantation Multidrug resistant organisms

Contacts and locations

Locations

  • Hvidovre Hospital, Copenhagen University

    Hvidovre, Copenhagen, 2650, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.